Market open
Nurix Therapeutics/$NRIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Ticker
$NRIX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
286
Website
NRIX Metrics
BasicAdvanced
$798M
-
-$2.88
2.14
-
Price and volume
Market cap
$798M
Beta
2.14
52-week high
$27.37
52-week low
$10.21
Average daily volume
965K
Financial strength
Current ratio
6.462
Quick ratio
6.375
Long term debt to equity
3.85
Total debt to equity
5.371
Management effectiveness
Return on assets (TTM)
-25.98%
Return on equity (TTM)
-53.22%
Valuation
Price to revenue (TTM)
12.932
Price to book
1.51
Price to tangible book (TTM)
1.51
Price to free cash flow (TTM)
-3.879
Growth
Revenue change (TTM)
-29.15%
Earnings per share change (TTM)
8.86%
3-year revenue growth (CAGR)
22.40%
3-year earnings per share growth (CAGR)
1.82%
What the Analysts think about NRIX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.
NRIX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NRIX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NRIX News
AllArticlesVideos
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
GlobeNewsWire·2 days ago
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
GlobeNewsWire·1 week ago
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nurix Therapeutics stock?
Nurix Therapeutics (NRIX) has a market cap of $798M as of April 04, 2025.
What is the P/E ratio for Nurix Therapeutics stock?
The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of April 04, 2025.
Does Nurix Therapeutics stock pay dividends?
No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Nurix Therapeutics dividend payment date?
Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nurix Therapeutics?
Nurix Therapeutics (NRIX) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.